The mRNA-based shot was initially approved as a booster in August, becoming Japan’s first home-grown shot for the coronavirus.
Four U.S. lawmakers have asked the Securities and Exchange Commission to investigate whether Elon Musk committed securities fraud by allegedly misleading investors about the safety of a brain implant being developed by the billionaire’s firm Neuralink, according to a letter to the regulator.
Tema ETFs has launched a new exchange traded fund that tracks popular drugmakers like Novo Nordisk and Eli Lilly, aiming to tap into growing demand for their weight-loss and diabetes drugs.
Medical device makers are seeing higher demand for their products due to a steady recovery in surgical procedures that were deferred during the pandemic, especially by older adults, as well as easing staff shortages at hospitals.
Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.
Weight loss was the talk of this earnings season, making names such as Wegovy, Ozempic and Mounjaro the water-cooler discussion that companies across the globe could not ignore.
Retail flows into Eli Lilly spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major received a highly anticipated approval for its weight-loss drug Zepbound.
To help cope with the high demand for weight-loss treatments, Eli Lilly is reportedly investing $2.17 billion in a German manufacturing facility after last week’s FDA approval of Zepbound for chronic weight management.
Data from the Phase III PRODROME study showed that AbbVie’s migraine drug Ubrelvy (ubrogepant), when given ahead of an expected episode, safely and effectively reduces the likelihood of developing moderate or severe headache, the company reported Thursday.
On the heels of cutting 100 jobs in Ireland, Pfizer is laying off around 500 workers from its Sandwich, Kent facility in the U.K. under its cost-reduction plan to save $3.5 billion through 2024.
